CIT Pharma - Clinical - Commercial Packing Services

Looking for a global partner offering you a wide and complete range of packing operations and the state-of-the-art serialization solutions fitting any regional metric? 👇 Here is what you need.   🌎 Due to our possibility to manage different regional requirements (EU, USA, UK, Russia, Canada, Australia, MENA, Japan and New Zealand), CIT Pharma can support any kind of project and assure your supply wherever you need.   📈 Your business deserves a flexible partner to reach its full potential: CIT Pharma can meet your needs in secondary packaging, even in challenging and not-standard cases and in minor markets.   Let us know your needs: 🖊️ e-mail to: federico.casaglia@citppharma.com   ➡️ follow us on LinkedIn: https://lnkd.in/dTjeRQur   #packaging #secondarypackaging #contractpackaging #pharmapackaging #packagingsolutions #citpharma #cmo #cdmo #pharma #pharmaceuticals #biologics #clinicaltrials #raredisease #citpharma

💡 Did you know that rare diseases affect more than 25 million Americans? The FDA’s ARC Program works to accelerate development of effective and safe treatment options for patients with rare diseases. 📲 Explore the program and its resources below and at: https://lnkd.in/dhVThF2d #ARCProgram

Italy ranks 2nd (with 78 facilities) in the top list of the Countries which have the most facilities in Europe who develop and manufacture Finished Dosage Forms of small molecules, following France (1st, 84 facilities) and followed by Germany (3rd, 75), as the PharmaSource infographic highlights.   According to the analysis, these leading Countries benefit from a well-established pharmaceutical industry, regulatory compliance, skilled workforce, advanced infrastructure, innovation, proximity to markets, and government support. Studies show that the EU Pharma CDMO market size is evaluated at USD 45.68 billion in 2025 and is forecasted to hit around USD 88.84 billion by 2034, growing at a CAGR of 7.62% from 2025 to 2034: https://lnkd.in/eUX9VexE   The Joint Research Centre of the European Commission emphasizes how the advanced manufacturing landscape is concentrated in a few countries, with Germany, Spain, France, and Italy together hosting almost 60% of all EU firms engaging in advanced manufacturing activities: https://lnkd.in/evpVSr9i   Cit Pharma is your partner of choice for advanced Contract Packaging Services for any pharmaceutical form and over all the main markets worldwide: do not hesitate to reach out and discover how we can support your business. 🖊️ e-mail to: federico.casaglia@citppharma.com ➡️ follow us on LinkedIn: https://lnkd.in/dTjeRQur   #packaging #secondarypackaging #contractpackaging #pharmapackaging #packagingsolutions #citpharma #cmo #cdmo #pharma #pharmaceuticals #biologics #clinicaltrials #raredisease #citpharma

Fake medicines traded are on the rise in the EU. This phenomenon includes medicines in high demand. 📈 ⚠️ If a medicine is prescription only, and your doctor doesn’t prescribe it to you, don’t just go online and try to get it anyway. This makes you vulnerable to fall for falsified medicines. Beware that when you buy medicines from unauthorised websites you are at greater risk of purchasing fakes.    Are you a wholesale distributor or a broker? 🔎 You can find on EMA's website practical recommendations on how to spot suspicious offers and what to do in such situation: https://lnkd.in/enawsxXR Fake medicines have a damaging impact on public health - let's all be vigilant. 📺 https://lnkd.in/eKyEhAXE   #EUvsFakeMedicines

Since 1986, when CIT Pharma was founded as pharma contractor, we have gone a long way alongside our People. Over time, our activity has expanded to track & trace, biopharma services, any form of secondary packaging, analysis & product release. Following the increasing market demand, and driven by a strong commitment to growth, in 1996 we opened a second factory site and in 2009 a third plant focused on the 4.0 pharma packaging service.   More than 30 years of success, and our potential is still enormous!   Dive into our history and check out all the packaging opportunities we offer. 🖊️ e-mail to: federico.casaglia@citppharma.com ➡️ follow us on LinkedIn: https://lnkd.in/dTjeRQur   #packaging #secondarypackaging #contractpackaging #pharmapackaging #packagingsolutions #citpharma #cmo #cdmo #pharma #pharmaceuticals #biologics #clinicaltrials #raredisease #citpharma #eugmp #usfda

EMA has established a regular procedure for manufacturers to request scientific advice on the intended clinical development strategy for high-risk medical devices. The advice procedure is available for two types of medical devices: ✅ class III devices – invasive and sustain or support human life ✅ class IIb active devices - intended to administer or remove medicines. Are you a manufacturer? Submit your request now! 🔗 Click the link for more information: https://lnkd.in/e6bJ-n9V

⚠️ Fake medicines are made by real criminals and can put your health at risk. Falsified medicines are on the rise. This is why EMA is joining forces with Europol and EUIPO - European Union Intellectual Property Office to raise awareness of the dangers of buying fakes from unauthorised websites.    Don’t fund organised crime or harm yourself—follow our recommendations to keep safe when buying medicines online.  ⚕️ 💻 Find out more: https://lnkd.in/eiyrmvSP   #EUvsFakeMedicines 

Thanks to all our #supplychain #exteralmanufacturing #purchasing partners this mess does not always rule in #pharmaceuticals 😉

Did you know that for specific needs you can ask directly a specialist in packaging solutions for an offer?   Discover the time and costs reduction you can achieve, at the highest qualitative standard, by working with a trusted partner like CIT Pharma!   CIT Pharma is a company focused exclusively on contract packaging, meaning that we are among the very few companies: 🔝 capable to handle every pharmaceutical form 🔝 in the leading world markets (EU GMP, US FDA, RU, MENA, …).   Interested in knowing all the packaging opportunities for your product? Contact a specialist! 🖊️ e-mail to: federico.casaglia@citppharma.com ➡️ follow us on LinkedIn: https://lnkd.in/dTjeRQur #packaging #secondarypackaging #contractpackaging #pharmapackaging #packagingsolutions #citpharma #cmo #cdmo #pharma #pharmaceuticals #biologics #clinicaltrials #raredisease #citpharma #eugmp #usfda

#Unmet #medical #needs evolve over time and change as the disease progresses and scientific progress is made. Therefore, the absence of a treatment or therapy is not the only unmet need to consider. The #quality of #life of #patients and their families and caregivers, the #burden of #treatment and the disease and its severity should also be considered in research and investment discussions concerning unmet medical needs.   For Chiesi’s R&D decisions, a broad understanding of UMN encourages continued research for all patient populations who can benefit from therapeutic innovation. In the #raredisease field, for example, once a clinical trial for a certain rare disease is opened, this generally boosts the knowledge around that disease, leading to other clinical trials and increased preclinical programs.   In this interview with Giorgio Iotti, read more about how Chiesi Group decides which disease areas to explore and invest in: https://lnkd.in/dX-yzjkB   Chiesi Global Rare Diseases #WeWontRest